10X Genomics Inc
$ 16.15
-2.06%
29 Dec - close price
- Market Cap 2,086,860,000 USD
- Current Price $ 16.15
- High / Low $ 16.47 / 15.95
- Stock P/E N/A
- Book Value 6.21
- EPS -0.63
- Next Earning Report 2026-02-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.10 %
- 52 Week High 20.34
- 52 Week Low 6.78
About
10X Genomics, Inc. is a premier life science technology company focused on pioneering genomic analysis solutions that empower researchers to investigate complex biological systems with exceptional precision. Headquartered in Pleasanton, California, the company develops a diverse array of advanced instruments, consumables, and analytical software that significantly enhance the depth and accuracy of genetic research. Operating globally across North America, Europe, and Asia, 10X Genomics plays a critical role in advancing genomic technologies, positioning itself as a cornerstone in the rapidly evolving arena of biological research and discovery, while addressing the dynamic needs of the life sciences industry.
Analyst Target Price
$17.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-10-29 | 2024-08-08 | 2024-04-30 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-03 | 2023-02-15 |
| Reported EPS | -0.0228 | 0.28 | -0.28 | -0.14 | -0.02 | -0.32 | -0.5 | -0.41 | -0.79 | -0.53 | -0.44 | -0.15 |
| Estimated EPS | -0.07 | -0.31 | -0.47 | -0.11 | -0.26 | -0.48 | -0.5 | -0.36 | -0.46 | -0.4 | -0.37 | -0.31 |
| Surprise | 0.0472 | 0.59 | 0.19 | -0.03 | 0.24 | 0.16 | 0 | -0.05 | -0.33 | -0.13 | -0.07 | 0.16 |
| Surprise Percentage | 67.4286% | 190.3226% | 40.4255% | -27.2727% | 92.3077% | 33.3333% | 0% | -13.8889% | -71.7391% | -32.5% | -18.9189% | 51.6129% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TXG
2025-11-19 21:09:35
10x Genomics, alongside the Garvan Institute and the University of Tokyo, launched the Asia-Pacific Spatial Translational Research Alliance (ASTRA) on November 18, 2025. This consortium aims to create a pan-cancer spatial atlas of 2,000 tumor samples using 10x Genomics' Xenium platform, focusing on ten major cancer types. ASTRA will establish regional hubs and a shared digital infrastructure to harmonize biospecimens and data, advancing precision oncology across the Asia-Pacific region.
2025-11-18 21:09:42
10x Genomics announced that its Chief Legal Officer, Eric S. Whitaker, will retire on January 1, 2026, after over eight years of service, transitioning to Strategic Counsel. Dr. Randy Wu will succeed him as General Counsel and Secretary. The company's stock (TXG) currently holds a "Hold" analyst rating with an $18 price target, and Spark’s AI Analyst describes TXG as Neutral, citing strong technical performance but weak financial results.
2025-11-17 05:09:23
The Asia-Pacific Spatial Translational Research Alliance (ASTRA) has been formed by researchers from the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan. This consortium, supported by 10x Genomics' Xenium platform, aims to create a comprehensive pan-cancer spatial atlas by mapping cancer and immune cell interactions across 2,000 tumor samples. The initiative seeks to advance precision oncology in the Asia-Pacific region by providing a shared foundation that integrates molecular and spatial data, addressing the current underrepresentation of these insights in global cancer data.
2025-11-17 05:09:23
10x Genomics (TXG) announced a planned legal leadership transition with Eric S. Whitaker retiring as Chief Legal Officer on January 1, 2026, after over eight years of service. He will transition to Strategic Counsel. Dr. Randy Wu, currently VP of Intellectual Property and Litigation, will succeed Whitaker as General Counsel and Secretary, also effective January 1, 2026.
2025-11-13 20:09:11
10x Genomics has launched the next generation of its Chromium Flex assay, featuring automation-compatible plate-based multiplexing that enables highly scalable and cost-effective single cell analysis. This new assay allows researchers to profile up to 384 samples and 100 million cells per week, expanding the scope of single cell studies to previously unachievable scales and applications. The technology aims to accelerate drug discovery and translational research by providing more data at a lower cost, addressing the growing need for high-quality biological data in AI-driven approaches.
2025-10-25 19:32:17
10x Genomics, Inc. (NASDAQ: TXG) is analyzed as a pioneering healthcare company focused on advanced life science technology. Despite current unprofitability with a negative P/E and EPS, the company shows promising revenue growth (12.90%) and a significant potential upside of 21.85% based on analyst target prices. Investors should consider its innovative product suite and positive market sentiment against the challenges of its growth phase.
